Stocks · Healthcare · Biotechnology
Spero Therapeutics, Inc. SPRO
$1.19 -5.56% Close, Oct 2, 2026 · NASDAQ · Market cap $68.9M
High qualityWeak trendInexpensive vs sector
Next earnings report: Nov 12, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin widened to 14.0% from -124.5% a year earlier.
- The stock is 60% below its highest close of the past year.
- Earnings beat analyst estimates in each of the last 6 quarters (average surprise over the last four: +100.0%).
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 22%
- Revenue growth, 3-year CAGRBottom 41%
- Revenue growth accelerationBottom 10%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 11%
- Gross marginTop 2%
- Operating marginTop 19%
- Cash conversion (OCF / net income)Top 24%
- Accruals (lower is better)Top 10%
- Net debt / EBITDA (lower is better)Top 5%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 4%
- Free-cash-flow yieldTop 2%
- EBITDA / enterprise valueTop 2%
- Sales / enterprise valueTop 3%
- P/E vs own 5-year history (lower is better)Bottom 44%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 11%
- 6-month returnBottom 4%
- 1-year return vs S&P 500Bottom 15%
- Distance from 52-week highBottom 15%
- Trend checklist (0–4)Bottom 38%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 4%
- Consecutive EPS beatsTop 12%
- Share of analysts rating BuyBottom 13%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 18%
- Maximum drawdown, 3 yearsTop 48%
- Beta vs S&P 500 (lower is better)Bottom 20%
- Net debt / EBITDA (lower is better)Top 5%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 22.8% | -7.0% | ↓ |
| Gross margin | -134.3% | 100.0% | ↑ |
| Operating margin | -124.5% | 14.0% | ↑ |
| FCF margin | -70.0% | 45.6% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -7.0% | 22.8% | ↓ | Bottom 22% |
| Gross margin | 100.0% | -134.3% | ↑ | Top 2% |
| Operating margin | 14.0% | -124.5% | ↑ | Top 19% |
| Net margin | 17.2% | -116.0% | ↑ | — |
| Free-cash-flow margin | 45.6% | -70.0% | ↑ | — |
| Return on invested capital | 12.6% | — | Top 11% | |
| Revenue growth, 3-year CAGR | 7.1% | — | Bottom 41% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 2.65×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -23.1%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 7.4%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -92.9 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- -6.33×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- 0.00%
- Shareholder yield
- 0.00%
- Share count change, 1 year
- +3.5%
- Share count change, 3-year CAGR
- +3.3%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 12, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 6
- Beats in the last 8 reports
- 6 of 8
- Average EPS surprise, last 4
- +100.0%
- Average 2-day reaction, last 8
- -0.6%
- Positive 20 days after report
- 2 of 8
Analysts
- Analysts with a rating
- 13
- Share rating Buy or Strong Buy
- 46%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 12, 2026 | +5.9% | -3.3% | -2.4% | -4.9% | — |
| May 13, 2026 | +27.8% | -3.9% | +2.0% | +0.0% | -50.4% |
| Mar 26, 2026 | +365.0% | -1.7% | +1.7% | +16.2% | -8.3% |
| Nov 13, 2025 | +48.0% | -8.3% | -10.5% | -11.7% | -11.3% |
| Aug 12, 2025 | +92.1% | +7.3% | -13.2% | -10.0% | +6.8% |
| May 13, 2025 | +54.5% | +13.1% | +13.0% | +367.2% | +255.7% |
| Mar 27, 2025 | -8.6% | -3.4% | -20.7% | -18.5% | +229.2% |
| Nov 14, 2024 | -18.5% | -4.6% | -8.4% | -16.0% | -38.4% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 12, 2026 | -$0.16 | -$0.17 | +5.9% | — |
| May 13, 2026 | -$0.13 | -$0.18 | +27.8% | $258,000 |
| Mar 26, 2026 | $0.53 | -$0.20 | +365.0% | $41.3M |
| Nov 13, 2025 | -$0.13 | -$0.25 | +48.0% | $3.0M |
| Aug 12, 2025 | -$0.03 | -$0.38 | +92.1% | $11.8M |
| May 13, 2025 | -$0.25 | -$0.55 | +54.5% | $5.9M |
| Mar 27, 2025 | -$0.38 | -$0.35 | -8.6% | $9.4M |
| Nov 14, 2024 | -$0.32 | -$0.27 | -18.5% | $13.5M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 10.8× | 10.5× | 50th | Top 4% |
| EV / EBITDA | 2.6× | — | — | Top 2% |
| EV / Sales | 0.47× | — | — | Top 3% |
| Free-cash-flow yield | 28.42% | — | — | Top 2% |
| Earnings yield | 9.24% | — | — | Top 4% |
P/E over the past five years
Range 3.8× – 38.0× since Sep 30, 2023. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
Technical state
Trend checklist
- ✓ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✓ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -19.0%
- 200-day average slope (20 days)
- -5.1%
- Distance from 50-day average
- -1.1%
- Distance from 200-day average
- -43.6%
- RSI (14)
- 46.8
- Relative volume
- 1.09×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 80.1%
- Volatility vs own 5-year history
- 78th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.80
- Correlation with S&P 500
- 0.14
- Current drawdown from 1-year high
- -60.1%
- Maximum drawdown, 3 years
- -68.9%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Dec 28, 2020 | Apr 8, 2025 | -97.5% | 1074 days | Not yet recovered |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $68.9M
- P/E (TTM)
- 10.8
- EPS, diluted (TTM)
- $0.11
- Revenue (TTM)
- $43.0M
- 52-week range
- $1.08 – $3.08
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $3.1M | $48.6M | $103.8M | $48.0M | $59.6M |
| Gross profit | $3.1M | $48.6M | $52.3M | -$48.8M | $59.6M |
| Operating income | -$88.0M | -$42.2M | $21.5M | -$73.4M | -$24,000 |
| Net income | -$89.8M | -$46.4M | $22.8M | -$68.6M | $8.6M |
| EPS (diluted) | -$2.91 | -$1.23 | $0.43 | -$1.27 | $0.15 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.5M | $15.0M | $5.9M | $11.8M | $3.0M | $39.7M | $258,000 | $0 |
| Net income | -$17.1M | -$20.9M | -$13.9M | -$1.7M | -$7.4M | $31.5M | -$7.2M | -$9.6M |
| EPS (diluted) | -$0.32 | -$0.39 | -$0.25 | -$0.03 | -$0.13 | $0.53 | -$0.13 | -$0.16 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$64.3M | -$7.7M | -$33.0M | -$23.4M | -$12.6M |
| Capital expenditure | $0 | $0 | $0 | $0 | $0 |
| Free cash flow | -$64.3M | -$7.7M | -$33.0M | -$23.4M | -$12.6M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $36.8M | $24.9M | $221,000 | $0 | $0 |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $50.8M
- Total assets
- $52.8M
- Total liabilities
- $8.6M
- Total debt
- $2.0M
- Net debt
- -$48.7M
- Shareholders’ equity
- $44.2M
As of Jun 30, 2026 (filed Aug 12, 2026).
Dividends
| Ex-date | Amount | Paid |
|---|---|---|
| Sep 16, 2015 | $0.02 | Oct 7, 2015 |
| Jun 17, 2015 | $0.02 | Jul 7, 2015 |
| Mar 18, 2015 | $0.02 | Apr 7, 2015 |
| Dec 17, 2014 | $0.02 | Jan 6, 2015 |
| Sep 17, 2014 | $0.02 | Oct 7, 2014 |
| Jun 18, 2014 | $0.02 | Jul 7, 2014 |
| Mar 19, 2014 | $0.02 | Apr 7, 2014 |
| Dec 17, 2013 | $0.02 | Jan 6, 2014 |
Short interest
- Shares sold short
- 976,488
- Days to cover
- 3.06
- Change vs previous report
- -19.3%
FINRA short interest, settlement date Sep 15, 2026.